Research Associate (In-Vivo)
King's College London - Breast Cancer Now Research Unit/Division of Cancer Studies
|Contract Type:||Contract / Temporary|
|Placed on:||14th October 2016|
|Closes:||14th November 2016|
|★ View Employer Profile|
The salary will be paid at Grade 6, £32,958 per annum, plus £2,623 per annum London Allowance.
This post will be Fixed Term Contract for 3 years
This is a Full-time post
A Research Associate (Post-Doc) is required to join the Breast Cancer Now Research Unit in an NC3Rs-funded project [https://www.nc3rs.org.uk/news/seven-project-grants-awarded] that will develop an in vitro reagent bank of patient-derived organoid (PDO) models of breast cancer and undertake to phenotypically cross validate matched PDO models with their in vivo patient-derived xenograft (PDX) models using proof of concept drug / target combinations relevant to molecular subtypes of breast cancer.
Breast cancer is a major cause of illness and death in women. In order to develop new treatment strategies we need to test therapies in models of breast cancer. We need models to faithfully recapitulate the biology of the patient’s tumour so they can help us predict what therapies will work in patients in the clinic. It is now widely recognised that patient-derived xenograft models (PDX) are gold-standard in vivo models of breast cancer. We, like others, have established PDX models of triple negative breast cancer. The post-holder, along with support from other members of the Unit, will develop patient-derived organoids (PDOs) using PDX and patient material grown in three-dimensional culture and undertake drug combination screening to ultimately benefit patient treatment. For each successful drug that enters the market, 250 have failed in animal-based preclinical testing. Moreover, of the drugs that do enter clinical testing, the majority fails due to lack of effectiveness and the presence of side effects. Clearly, there is an urgent need to improve current laboratory testing to prevent ineffective drugs from entering the costly and undesirable pre-clinical animal testing phase. In concordance with the principles of NC3Rs funding organisation, we anticipate that this project could lead to a dramatic reduction and replacement of the number of exploratory pre-clinical PDX in vivo experiments that take place.
The post holder will have a PhD in Cell Biology (or related discipline) with a strong emphasis on primary cell culture or organoid model generation. The post will require significant cell culture experience, and knowledge of breast cancer models and tumour xenograft pre-clinical testing would be an advantage. The post-holder will be able to work independently and will also demonstrate good interpersonal skills and collaborative working practices.
The post will be based in Professor Tutt’s own laboratory at the Guy’s Hospital Campus, but will also involve interaction with colleagues at the Breast Cancer Research Centre at the Institute of Cancer Research, London also directed by Professor Andrew Tutt.. Professor Tutt’s laboratory has published work in Cancer Discovery, Cancer Research, Science Translational Medicine, Science Signalling, Breast Cancer Research and Breast Cancer Research and Treatment in the last year.
The selection process will include a written assessment and a panel interview.
For informal discussion to find out more about the role please contact Dr Rebecca Marlow at firstname.lastname@example.org
To apply for this role, please go to the King’s College London HireWire Job Board and register to download and submit the specified application form.
The deadline for applications is midnight on Monday 14 November 2016.
Share this job
Type / Role: